Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01265927 · ClinicalTrials.gov registry record · Phase 1
A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer
A Phase 1 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01265927 is a Phase 1 study that has completed, run by Indiana University. The registered enrollment target is 10 participants.
The verdict
NCT01265927, a Phase 1 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
A study to evaluate safety and biologic effects of giving GRN163L in combination with trastuzumab in patients diagnosed with HER2+ metastatic breast cancer that is resistant to therapy with trastuzumab.
Interventions
- DRUG GRN163L in combination with trastuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2011-01 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01265927
The ClinicalTrials.gov registry entry for NCT01265927 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GRN163L in combination with trastuzumab is the first listed.
NCT01265927 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01265927 about?
NCT01265927 is a clinical study titled "A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer". A study to evaluate safety and biologic effects of giving GRN163L in combination with trastuzumab in patients diagnosed with HER2+ metastatic breast cancer that is resistant to therapy with trastuzumab.
What is the current status of trial NCT01265927?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2011-01. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01265927?
The interventions under investigation include: GRN163L in combination with trastuzumab (DRUG).
Who is sponsoring clinical trial NCT01265927?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.